Mapi - Pharma (Mapi - Pharma) Median PS Value : $0.00 (As of May. 30, 2024)

View and export this data going back to . Start your Free Trial

What is Mapi - Pharma Median PS Value?

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Mapi - Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2015 was $0. Mapi - Pharma's 10-Year median PS Ratio is . Therefore, the Median PS Value for today is $0.00.

As of today (2024-05-30), Mapi - Pharma's share price is $0.00. Mapi - Pharma's Median PS Value is $0.00. Therefore, Mapi - Pharma's Price to Median PS Value for today is 0.00.

The historical rank and industry rank for Mapi - Pharma's Median PS Value or its related term are showing as below:

MAPI's Price-to-Median-PS-Value is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 0.82
* Ranked among companies with meaningful Price-to-Median-PS-Value only.

Mapi - Pharma Median PS Value Historical Data

The historical data trend for Mapi - Pharma's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mapi - Pharma Median PS Value Chart

Mapi - Pharma Annual Data

Trend

Dec12

Dec13

Dec14

Median PS Value

Mapi - Pharma Semi-Annual Data
	Dec12	Dec13	Jun14	Dec14	Jun15
Median PS Value	-	-	-	-	-

Competitive Comparison of Mapi - Pharma's Median PS Value

For the Drug Manufacturers - Specialty & Generic subindustry, Mapi - Pharma's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mapi - Pharma's Price-to-Median-PS-Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mapi - Pharma's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where Mapi - Pharma's Price-to-Median-PS-Value falls into.

Mapi - Pharma Median PS Value Calculation

Mapi - Pharma's Median PS Value for today is calculated as

Median PS Value	=	Revenue per Share (TTM)	*	10-Year Median PS Ratio
	=	0	*
	=	0.00

10-Year Median PS Ratio is .
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Mapi - Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2015 was $0.

Mapi - Pharma (NAS:MAPI) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

Mapi - Pharma's Price to Median PS Value for today is calculated as

Price to Median PS Value	=	Share Price	/	Median PS Value
	=	0.00	/	0.00
	=

Mapi - Pharma Median PS Value Related Terms

Thank you for viewing the detailed overview of Mapi - Pharma's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Mapi - Pharma (Mapi - Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mapi - Pharma Ltd (NAS:MAPI) » Definitions » Median PS Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.mapi-pharma.com

Mapi - Pharma Ltd was incorporated under the laws of the State of Israel on January 29, 2008. It is a development stage pharmaceutical company, engaged in the development of high-barrier to entry and high-added value generic drugs that include complex active pharmaceutical ingredients or APIs, formulations and life cycle management or LCM products that target large markets. The Company is developing two LCM products for the treatment of multiple sclerosis and neuropathic pain. It is also developing a portfolio of approximately 13 complex APIs. Its LCM portfolio focuses on market product, consisting of Glatiramer Acetate Depot, a once-monthly injection for the treatment of MS, Pregabalin ER, extended release capsules for the treatment of neuropathic pain and epilepsy, and Risperidone LAI, a depot formulation of Risperdal Consta, expected to be developed under the abbreviated new drug application ANDA or 505(b)(2) shortened regulatory pathway. Its competitors in the generic pharmaceutical products and LCM markets includes Teva Pharmaceutical Industries Ltd.; Impax Laboratories, Inc.; Alkermes Plc.; Momenta Pharmaceuticals, Inc.; and Andrx Corporation; a private U.S. company. The Company's current patent portfolio contains approximately 20 patent applications for complex APIs, formulations, polymorphs, and routes of synthesis. Its operations are subject to many governmental regulations.